According to the information provided by the Health Bureau (SSM) to the Macau Business Newspaper, the drug is still used by patients in Macau who are willing to receive TCM treatment.

During the "618 epidemic" in Macau last year, "the Chinese medical anti-epidemic team opened a hotline from July 1 to August 23 to provide telephone assessments to COVID-19 patients who were staying in quarantine hotels and were willing to receive TCM treatment to determine whether they were suitable for TCM treatment," de SSM added.

The SSM still said: "If appropriate, the team will determine which PCM to use Lianhua Qingwen capsule, Huoxiang Zhengqi softgel/oral liquid based on their clinical symptoms and physical condition, and provide them with instructions on dosage, administration and precautions." .

Data provided by SSM to Macau business shows that more than 1,300 patients have received TCM treatment; "Most of them used Lianhua Qingwen capsule, reflecting the obvious relief of dry mouth, sore throat and cough symptoms after the use of proprietary Chinese medicine, and will continue to use Chinese medicine as appropriate according to national and local diagnosis and treatment plans, as well as the symptoms and physique of COVID-19 patients." "

In October, during the Macau 2022 CHEXPO, Yiling Pharmaceutical highlighted that Lianhua Qingwen Capsule, a "top brand for the treatment of respiratory infectious diseases," has been included in the Chinese government's treatment plan or expert consensus on the prevention and control of influenza A, influenza B, avian influenza and the novel coronavirus pneumonia for 30 times. Lianhua Qingwen has a remarkable curative effect and is widely used not only in China, but also in other countries in the fight against COVID-19. So far, Lianhua Qingwen has been approved to enter the market in nearly 30 countries around the world, becoming the most widely registered Chinese medicine overseas. "